Literature DB >> 16243797

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.

Ie-Ming Shih1, Robert J Kurman.   

Abstract

Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243797     DOI: 10.1158/1078-0432.CCR-05-0755

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.

Authors:  Elisabetta Kuhn; Alan K Meeker; Kala Visvanathan; Amy L Gross; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

4.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Authors:  Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Gynecol Oncol       Date:  2011-07-02       Impact factor: 5.482

5.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 6.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

Review 7.  Ovarian cancer update: lessons from morphology, molecules, and mice.

Authors:  Kathleen R Cho
Journal:  Arch Pathol Lab Med       Date:  2009-11       Impact factor: 5.534

8.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

9.  Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.

Authors:  Kuan-Ting Kuo; Bin Guan; Yuanjian Feng; Tsui-Lien Mao; Xu Chen; Natini Jinawath; Yue Wang; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Kyu-Rae Kim; Joo-Hyun Nam; Young-Tak Kim
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.